speb/financial-data huggingface dataset:
Financial scorecard for AAM.AX (Basic Materials — Gold, Australia)
Report date: 2025-12-31 (annual)
Stock price: 0.020833333333333332
Market cap: 48031740 (USD: 32236067.11409396)
P/B ratio: 23.641740481424957
Debt to equity: 0.0025
Current ratio: 8.7
Return on net tangible assets (%): -465.1023346812279
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 1 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0.3825782701188839
Debt paydown yield (%): 0.06380086292162909
Total shareholder yield (%): 0.446379133040513 (Low Return)
Momentum (%): 1m -24.47916666666668, 3m -27.083333333333343, 6m -23.958333333333343, 12m -21.35416666666667, composite -15.634578544061306 (Flat)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 9, recommendation: Short
Revenue deceleration: no
Accrual ratio: 0.0020983748550393753
FCF conversion rate: 1.0060493137115376
Beneish M-score: -3.1146739303352065 (Likely Safe)
ROE (%): -43.789501976924136
Equity multiplier (leverage): 1.2623885293623325
ROE archetype: Low Return
Treasury beta 1y: -0.0011236999828741674 (R-squared: 7.842562363255676e-06)
Insider 90-day net shares: 2201064 (net value USD: 68086.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 62.03966005665722, ROIC , revenue growth 1y , 6m momentum 34.13597733711048
Sector percentiles: P/E , 6m momentum 48.66740699611327
Industry median P/E: 8.322060300477567; industry median ROIC: -7.9824265928961236
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.11178001920251532
Base cash flow: -7687005.369127517
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ABSI (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 7.56
Market cap: 1280666496 (USD: 1280666496)
P/B ratio: 2.9551552238458814
Debt to equity: 0.025699999999999997
Current ratio: 6.59
Interest coverage ratio: -1713.6666666666667
Return on net tangible assets (%): -20.500293438412232
Buffett classification: The Gruesome
Analyst consensus upside (%): 359.3333333333333
Rule of 40 score: -14353.899821109122
Altman Z-score: 28.012561464219683 (Safe Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.06926081089576658
Total shareholder yield (%): 0.06926081089576658 (Low Return)
Momentum (%): 1m -24.92552135054618, 3m 91.87817258883248, 6m 159.79381443298965, 12m 115.3846153846154, composite 146.18885797213636 (Strong Uptrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 8, recommendation: Short
Revenue growth 1y (%): -81.76420695504665
Revenue deceleration: no
Accrual ratio: -0.015839180363689333
FCF conversion rate: 0.8897935741072334
Beneish M-score: -3.5230494412955666 (Likely Safe)
ROE (%): -16.379281722096177
Net margin (%): -13766.976744186048
Asset turnover: 0.0010439680497220131
Equity multiplier (leverage): 1.1396436279121245
ROE archetype: Low Return
Treasury beta 1y: -0.00796793148526381 (R-squared: 0.0010752768888717494)
Insider 90-day net shares: 50353 (net value USD: 349614.00)
ROIC (%): -196.35787471016073 (pretax: -248.55427178501358)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 32.942238267148014, ROIC 30.595667870036102, revenue growth 1y 27.166064981949457, 6m momentum 1.263537906137184
Sector percentiles: P/E , 6m momentum 0.8954154727793696
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.15
Base cash flow: -103646000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ACAD (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 24.84
Market cap: 4253499136 (USD: 4253499136)
P/E ratio: 10.07239819004525
P/B ratio: 3.054093666681089
Debt to equity: 0.0407
Current ratio: 3.59
Return on net tangible assets (%): 0.12417954365331313
Buffett classification: The Gruesome
Analyst consensus upside (%): 47.349505840071856
Rule of 40 score: -0.35915703834826207
Altman Z-score: 6.315525247148804 (Safe Zone)
Piotroski F-score: 5 (Neutral)
Magic formula: return on capital % 12.479520493794233, earnings yield % 3.035505542965013, rank 3091
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.03274950706372966
Total shareholder yield (%): 0.03274950706372966 (Low Return)
Momentum (%): 1m 6.335616438356166, 3m 13.11475409836065, 6m -7.451564828614009, 12m 7.765726681127978, composite 2.336030551954591 (Flat)
Lynch category: Slow Grower (confidence: Medium)
Screener: long score 6, short score 4, recommendation: Neutral
Revenue growth 1y (%): 9.718930733432396
Net income growth 1y (%): -80.84478853952704
Revenue deceleration: no
Accrual ratio: -0.015859028057139703
FCF conversion rate: 7.910090734121528
Beneish M-score: -2.626058571357006 (Likely Safe)
ROE (%): 0.2938448512112516
Net margin (%): 1.356775671299923
Asset turnover: 0.16915497290517997
Equity multiplier (leverage): 1.2803398646552393
ROE archetype: Low Return
P/E z-score: 3.046247950359184
FCF z-score: 3.986360417110671
Treasury beta 1y: -0.005694635234612178 (R-squared: 0.00463759113471227)
Insider 90-day net shares: -25399 (net value USD: -600731.00)
ROIC (%): 18.004416263853827 (pretax: 22.790400333992185)
Incremental ROIC 3y (%): 62.6215070685323 (pretax: 79.26773046649657)
Capital allocation category: High-Efficiency Compounder
Industry percentiles: P/E 8.032490974729242, P/B 33.935018050541515, ROIC 4.061371841155235, revenue growth 1y 15.072202166064983, 6m momentum 33.2129963898917
Sector percentiles: P/E 19.770773638968482, 6m momentum 37.57163323782235
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.09047075068352045
Base cash flow: 398070000
DCF price per share: base 97.9137009929693, conservative 57.08895765787693, aggressive 171.5062092086568
Financial scorecard for ADC.AX (Basic Materials — Other Industrial Metals & Mining, Australia)
Report date: 2025-06-30 (annual)
Stock price: 0.02777777777777778
Market cap: 5278426 (USD: 3449951.633986928)
Current ratio: 3.13
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 1 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 0.6944444444444402, 3m -35.18518518518518, 6m -32.407407407407405, 12m -16.11111111111111, composite -28.094082588335457 (Strong Downtrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 0, short score 4, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -2.48 (Likely Safe)
ROE archetype: Standard Business
Treasury beta 1y: -1.4467016406643151e-05 (R-squared: 2.5046176123995086e-09)
Insider 90-day net shares: 0 (net value USD: 0.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B , ROIC , revenue growth 1y , 6m momentum 44.12989175686928
Sector percentiles: P/E , 6m momentum 56.19100499722376
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.05
Base cash flow: 0
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ADGM (Healthcare — Medical Devices, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 0.48
Market cap: 10705442 (USD: 10705442)
P/B ratio: 4.461489580786026
Debt to equity: 4.2077
Current ratio: 1.85
Interest coverage ratio: -6.683804627249358
Buffett classification: The Gruesome
Analyst consensus upside (%): 189.56521739130437
Rule of 40 score: 0
Altman Z-score: -3.6783031573506295 (Distress Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -21.77397252724362
Total shareholder yield (%): -21.77397252724362 (Minimal or Negative)
Momentum (%): 1m -23.809523809523814, 3m -68.21192052980133, 6m -55.55555555555556, 12m -72.09302325581396, composite -62.37985636953757 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 0, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue deceleration: no
Accrual ratio: -0.06945167815312314
FCF conversion rate: 0.5901358112937812
Beneish M-score: -2.6037258466167086 (Likely Safe)
ROE (%): -77.17769073757378
Asset turnover: 0
Equity multiplier (leverage): 4.55458708004634
ROE archetype: Low Return
Treasury beta 1y: 0.032834363212325655 (R-squared: 0.016949852416045862)
Insider 90-day net shares: 222315 (net value USD: 243946.00)
ROIC (%): -101.39607153327471 (pretax: -128.3494576370566)
Incremental ROIC 3y (%): 1.4705010949375241 (pretax: 1.861393791060157)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 47.47774480712167, ROIC 57.566765578635014, revenue growth 1y , 6m momentum 69.73293768545994
Sector percentiles: P/E , 6m momentum 72.56446991404012
Industry median P/E: 21.626420273203117; industry median ROIC: -5.9391058628332924
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.0699490081440658
Base cash flow: -24488000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for AER.AX (Technology — Software - Application, Australia)
Report date: 2025-06-30 (annual)
Stock price: 0.034722222222222224
Market cap: 4298187 (USD: 2809272.5490196077)
P/B ratio: 5.347643512594345
Debt to equity: 0
Current ratio: 2.26
Interest coverage ratio: -111.58934876422126
Return on net tangible assets (%): -61.71547442272857
Buffett classification: The Gruesome
Rule of 40 score: 10.713088811062342
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -28.07539682539683, 3m -39.236111111111114, 6m -43.672839506172835, 12m -41.74382716049382, composite -33.97092734496949 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 3, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -2.48 (Likely Safe)
Equity multiplier (leverage): 1.7633404662356944
ROE archetype: Standard Business
Treasury beta 1y: 0.002229582531007958 (R-squared: 0.00020058843245960496)
Insider 90-day net shares: 0 (net value USD: 0.00)
Incremental ROIC 3y (%): -297.74223320899 (pretax: -376.88890279618977)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 55.79514824797843, ROIC , revenue growth 1y , 6m momentum 79.64959568733153
Sector percentiles: P/E , 6m momentum 74.74140807474141
Industry median P/E: 2.1394954536591486; industry median ROIC: 6.21806735836372
Sector median P/E: 1.5433673469387754; sector median ROIC: 6.677876317240262
WACC: 0.06395
Base cash flow: -412630.0653594771
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for AGY.AX (Basic Materials — Other Industrial Metals & Mining, Australia)
Report date: 2025-12-31 (annual)
Stock price: 0.02777777777777778
Market cap: 63281904 (USD: 42471076.51006711)
P/E ratio: 25.336434019366813
P/B ratio: 2.1489408486333703
Debt to equity: 0.0011
Current ratio: 16.32
Interest coverage ratio: 580.1990459070796
Return on net tangible assets (%): 8.575341461908021
Buffett classification: The Great
Rule of 40 score: 0
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.09616392112419248
Total shareholder yield (%): 0.09616392112419248 (Low Return)
Momentum (%): 1m -19.444444444444436, 3m -51.38888888888889, 6m -63.13131313131313, 12m 4.861111111111119, composite -28.11592940903286 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 2, recommendation: Neutral
Revenue deceleration: no
Accrual ratio: 0.12024570405804978
FCF conversion rate: -0.3448282654622915
Beneish M-score: -2.2508709415679578 (Likely Safe)
Equity multiplier (leverage): 1.0058868047201666
ROE archetype: Standard Business
P/E z-score: 1.1059370719365353
Treasury beta 1y: -0.002027336748077217 (R-squared: 2.7940384093590328e-05)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): 10.231097003660985 (pretax: 10.231097003660985)
Incremental ROIC 3y (%): 47.52499828702101 (pretax: 50.825709465015066)
Capital allocation category: Standard Allocator
Industry percentiles: P/E 13.57202331390508, P/B 28.975853455453787, ROIC 3.413821815154038, revenue growth 1y , 6m momentum 75.43713572023314
Sector percentiles: P/E 31.81565796779567, 6m momentum 79.59466962798444
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.08546821456229578
Base cash flow: 4960410.067114094
DCF price per share: base 0.08486669327410966, conservative 0.0600421563458546, aggressive 0.12176995145669244
Financial scorecard for AHCO (Healthcare — Medical Devices, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 10.7
Market cap: 1463942656 (USD: 1463942656)
P/B ratio: 1.0690424038333923
Debt to equity: 1.3211000000000002
Current ratio: 0.93
Interest coverage ratio: 0.2144643275767758
Buffett classification: The Gruesome
Analyst consensus upside (%): 18.82352941176471
Rule of 40 score: -63.74596208201887
Altman Z-score: 0.22432662014856727 (Distress Zone)
Piotroski F-score: 4 (Weak)
Magic formula: return on capital % 0.7424952385074886, earnings yield % 0.16179747506848588, rank 2752
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -6.687898572988914
Total shareholder yield (%): -6.687898572988914 (Minimal or Negative)
Momentum (%): 1m 6.679960119641076, 3m -16.40625000000001, 6m 6.045589692765108, 12m 16.0520607375271, composite -0.525136949844755 (Flat)
Lynch category: Turnaround (confidence: High)
Screener: long score 0, short score 6, recommendation: Neutral
Revenue growth 1y (%): 5.83164361354831
Revenue deceleration: no
Accrual ratio: 0.002886992448101866
FCF conversion rate: 1.8483157399314194
Beneish M-score: -4.222589436315647 (Likely Safe)
ROE (%): -0.9782278048082663
Net margin (%): -2.421043036062521
Asset turnover: 0.14056772407884874
Equity multiplier (leverage): 2.874430948383734
ROE archetype: Low Return
FCF z-score: 3.968343301903255
Treasury beta 1y: 0.00041282255467093074 (R-squared: 1.464759767539299e-05)
Insider 90-day net shares: -22550 (net value USD: -231137.00)
ROIC (%): 4.4282477095914885 (pretax: 5.605376847584162)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 16.320474777448073, ROIC 25.519287833827892, revenue growth 1y 33.82789317507419, 6m momentum 14.836795252225517
Sector percentiles: P/E , 6m momentum 22.564469914040114
Industry median P/E: 21.626420273203117; industry median ROIC: -5.9391058628332924
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.07832292390093087
Base cash flow: -66499000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for AHR.V (Basic Materials — Other Industrial Metals & Mining, Canada)
Report date: 2026-03-31 (annual)
Stock price: 0.7021276595744681
Market cap: 223074096 (USD: 160484961.15107915)
Debt to equity: 35.3322
Current ratio: 1.43
Interest coverage ratio: -209.0221674635042
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: -5.904178707228482 (Distress Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -0.038533864519199955
Total shareholder yield (%): -0.038533864519199955 (Minimal or Negative)
Momentum (%): 1m 8.37187789084181, 3m 0.19946808510639624, 6m -34.53133985048879, 12m 38.39037927844589, composite -2.2107804163168203 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 1, short score 9, recommendation: Short
Revenue deceleration: no
Accrual ratio: -0.5845826355017574
FCF conversion rate: -0.21805481143909616
Beneish M-score: -51.70537535904762 (Likely Safe)
Asset turnover: 0
ROE archetype: Standard Business
FCF z-score: 3.8238447259747517
Treasury beta 1y: -0.0031403056881946774 (R-squared: 0.0003819200772970205)
Insider 90-day net shares: -140600 (net value USD: -121082.00)
Incremental ROIC 3y (%): -96.74752548986334 (pretax: -122.46522213906749)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B , ROIC , revenue growth 1y , 6m momentum 47.96003330557868
Sector percentiles: P/E , 6m momentum 58.57856746252082
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.09139907432887186
Base cash flow: -654199.2805755396
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for AI (Technology — Software - Infrastructure, United States)
Report date: 2026-04-30 (annual)
Stock price: 8.15
Market cap: 1266911616 (USD: 1266911616)
P/B ratio: 2.052329077202176
Debt to equity: 0.0898
Current ratio: 6.64
Return on net tangible assets (%): -70.2349929416376
Buffett classification: The Gruesome
Rule of 40 score: -217.81815406304247
Altman Z-score: 0.7251103621781597 (Distress Zone)
Piotroski F-score: 6 (Neutral)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -0.016102149307312057
Total shareholder yield (%): -0.016102149307312057 (Minimal or Negative)
Momentum (%): 1m -12.553648068669526, 3m -5.6712962962962985, 6m -35.77620173364854, 12m -68.65384615384616, composite -35.200448061263664 (Strong Downtrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 13, recommendation: Short
Revenue growth 1y (%): -35.67301365356143
Revenue CAGR 3y (%): -2.1090494642777458
Revenue deceleration: yes
Revenue growth consistency score: 26.942952605586985
Accrual ratio: -0.30207338687569724
FCF conversion rate: 0.40847930029402446
Beneish M-score: -3.9228257288986867 (Likely Safe)
ROE (%): -16.831776898743396
Net margin (%): -223.97093023255815
Asset turnover: 0.06027864856671743
Equity multiplier (leverage): 1.2467368761396538
ROE archetype: Low Return
Treasury beta 1y: 0.007988216650338918 (R-squared: 0.0028855761872349723)
Insider 90-day net shares: -1617709 (net value USD: -15665083.00)
ROIC (%): -459.30363976680695 (pretax: -581.3970123630468)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 28.95927601809955, ROIC 72.62443438914026, revenue growth 1y 55.88235294117647, 6m momentum 70.13574660633483
Sector percentiles: P/E , 6m momentum 69.96996996996997
Industry median P/E: 5.36821412369575; industry median ROIC: 3.7232145830700096
Sector median P/E: 1.5433673469387754; sector median ROIC: 6.677876317240262
WACC: 0.15
Base cash flow: -458723000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for AKO.AX (Basic Materials — Other Industrial Metals & Mining, Australia)
Report date: 2025-12-31 (annual)
Stock price: 0.05555555555555556
Market cap: 18261176 (USD: 12255822.818791946)
P/B ratio: 1.1189040301297912
Debt to equity: 0
Current ratio: 6.19
Return on net tangible assets (%): -21.545811668217162
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 1.4300283837141705
Total shareholder yield (%): 1.4300283837141705 (Low Return)
Momentum (%): 1m 0.6944444444444402, 3m -2.77777777777778, 6m -9.876543209876532, 12m -23.73737373737373, composite -12.305881290555613 (Strong Downtrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 2, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -2.3098690622382856 (Likely Safe)
ROE (%): -14.17114777321214
Equity multiplier (leverage): 1.0190061138973665
ROE archetype: Low Return
Treasury beta 1y: 0.002182571336559368 (R-squared: 0.00016254856427164977)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -10.913436481328933 (pretax: -13.81447655864422)
Incremental ROIC 3y (%): -6.758228212832062 (pretax: -8.554719256749447)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 17.485428809325562, ROIC 26.644462947543712, revenue growth 1y , 6m momentum 26.81099084096586
Sector percentiles: P/E , 6m momentum 34.952803997779014
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.07165
Base cash flow: -2247621.476510067
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for AKTS (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 23.89
Market cap: 1320578176 (USD: 1320578176)
P/B ratio: 1.8877563998593188
Debt to equity: 0.0229
Current ratio: 19.49
Return on net tangible assets (%): -3.858267405375928
Buffett classification: The Gruesome
Analyst consensus upside (%): 92.17439910564562
Rule of 40 score: 322.29894473393233
Altman Z-score: 11.73304458139692 (Safe Zone)
Piotroski F-score: 5 (Neutral)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -0.0021960078189267305
Total shareholder yield (%): -0.0021960078189267305 (Minimal or Negative)
Momentum (%): 1m -16.759581881533098, 3m 12.370649106302912, 6m 10.346420323325646, 12m , composite 11.35853471481428 (Moderate Uptrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 7, recommendation: Neutral
Revenue growth 1y (%): 245.87352625937834
Revenue deceleration: no
Accrual ratio: 0.01846531842040856
FCF conversion rate: 1.4240654843110505
Beneish M-score: 8.629074617554886 (Strong Manipulation Signal)
ROE (%): -10.181715139779808
Net margin (%): -567.8648899907034
Asset turnover: 0.007667942676960291
Equity multiplier (leverage): 2.338282971116155
ROE archetype: Low Return
Treasury beta 1y: 0.006523767580034767 (R-squared: 0.0028014354146271504)
Insider 90-day net shares: -107921 (net value USD: -2972792.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 22.382671480144403, ROIC , revenue growth 1y 2.3465703971119134, 6m momentum 20.75812274368231
Sector percentiles: P/E , 6m momentum 19.949856733524353
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.052851
Base cash flow: -70986000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ALAB (Technology — Semiconductors, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 291.58
Market cap: 49979121664 (USD: 49979121664)
P/E ratio: 83.66412213740458
P/B ratio: 12.574942444047583
Debt to equity: 0.027999999999999997
Current ratio: 11.3
Return on net tangible assets (%): 5.435411026558377
Buffett classification: The Great
Analyst consensus upside (%): 170.99452554744525
Rule of 40 score: 19.83112419578707
Altman Z-score: 182.7654034329594 (Safe Zone)
Piotroski F-score: 7 (Neutral)
Magic formula: return on capital % 4.4642702431079, earnings yield % 0.12661226356465258, rank 2038
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -27.09041808361673, 3m 36.99492576583348, 6m 71.86136979842036, 12m 139.62853385930308, composite 112.50721576884287 (Strong Uptrend)
Lynch category: Slow Grower (confidence: Medium)
Screener: long score 8, short score 2, recommendation: Neutral
Revenue growth 1y (%): 93.40010787621831
Net income growth 1y (%): 152.39636695056413
Revenue deceleration: no
Accrual ratio: 0.008334592066907382
FCF conversion rate: 0.834416635537293
Beneish M-score: -1.6804758914299844 (Possible Manipulation)
ROE (%): 5.6208360774948884
Net margin (%): 26.044149551986145
Asset turnover: 0.19326689309246708
Equity multiplier (leverage): 1.1166916644911677
ROE archetype: Standard Business
P/E z-score: 1.0655610988028121
FCF z-score: 2.190153642116281
Treasury beta 1y: 0.005181871867295188 (R-squared: 0.0005055783543379155)
Insider 90-day net shares: -1667737 (net value USD: -443124821.00)
ROIC (%): 76.55403880109967 (pretax: 96.90384658367046)
Incremental ROIC 3y (%): 43.34338414712907 (pretax: 54.86504322421402)
Capital allocation category: High-Efficiency Compounder
Industry percentiles: P/E 43.20987654320987, P/B 67.90123456790124, ROIC 1.8518518518518516, revenue growth 1y 8.024691358024691, 6m momentum 18.51851851851852
Sector percentiles: P/E 51.41808475141808, 6m momentum 6.072739406072739
Industry median P/E: 31.956834532374103; industry median ROIC: 3.679818125534067
Sector median P/E: 1.5433673469387754; sector median ROIC: 6.677876317240262
WACC: 0.15
Base cash flow: 188419000
DCF price per share: base 26.91763186068062, conservative 19.42320071411511, aggressive 39.38123100401134
Financial scorecard for ALEX.V (Basic Materials — Other Precious Metals & Mining, British Virgin Islands)
Report date: 2026-03-31 (quarterly)
Stock price: 0.3546099290780142
Market cap: 52822516 (USD: 38001810.07194245)
P/B ratio: 2.813171460792754
Debt to equity: 0
Current ratio: 0.75
Interest coverage ratio: -108.379466532461
Return on net tangible assets (%): -1.2666736354084605
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: 63.44757865481604 (Safe Zone)
Piotroski F-score: 1 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -1.2654707272980137, 3m -30.59777102330293, 6m -11.025145067698267, 12m -30.10586905128995, composite -23.610986318964063 (Strong Downtrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 4, short score 9, recommendation: Short
Net income growth 1y (%): -2214.1814366385847
Revenue deceleration: no
Accrual ratio: 0.030346371775604335
FCF conversion rate: 3.5074076409027866
Beneish M-score: -2.5246477367080944 (Likely Safe)
ROE (%): -1.2411765231538217
Asset turnover: 0
Equity multiplier (leverage): 1.0255379196161154
ROE archetype: Low Return
Treasury beta 1y: 0.005793650040302424 (R-squared: 0.001401864906638553)
Insider 90-day net shares: 152500 (net value USD: 60367.00)
ROIC (%): -3.029821795487176 (pretax: -3.8352174626419946)
Incremental ROIC 3y (%): 0.4976505426734226 (pretax: 0.6299373957891432)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 25.787965616045845, ROIC 14.040114613180515, revenue growth 1y , 6m momentum 20.630372492836678
Sector percentiles: P/E , 6m momentum 35.86896168795114
Industry median P/E: 8.740359897172237; industry median ROIC: -12.638421644657798
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.12940000000000002
Base cash flow: -61169.34306569342
DCF price per share: base 0, conservative 0.0009851502933026304, aggressive 0
Financial scorecard for ALMR (Healthcare — Medical Devices, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 25.88
Market cap: 1793773440 (USD: 1793773440)
Debt to equity: 1.8541999999999998
Current ratio: 5.88
Interest coverage ratio: -55.36771300448431
Buffett classification: The Gruesome
Rule of 40 score: 12.101596604712782
Altman Z-score: 2.201989020213576 (Grey Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 8.602601762484268, 3m 4.186795491143314, 6m , 12m , composite 4.186795491143314 ()
Lynch category: Speculative (confidence: Low)
Screener: long score 1, short score 8, recommendation: Short
Revenue deceleration: no
Accrual ratio: -0.001072667885932497
FCF conversion rate: 0.9906213364595545
Beneish M-score: 2.0928781081161567 (Strong Manipulation Signal)
Net margin (%): -81.90896869598618
Asset turnover: 0.1396345420512628
ROE archetype: Standard Business
Treasury beta 1y: 0.0048262521234069735 (R-squared: 0.0035414263909868023)
Insider 90-day net shares: 470588 (net value USD: 10352936.00)
Capital allocation category: Standard Allocator
Industry median P/E: 21.626420273203117; industry median ROIC: -5.9391058628332924
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.05
Base cash flow: -31328000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ALMS (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 28
Market cap: 3569775616 (USD: 3569775616)
P/B ratio: 4.795604653372627
Debt to equity: 0.0629
Current ratio: 7.51
Return on net tangible assets (%): -17.894361530203735
Buffett classification: The Gruesome
Analyst consensus upside (%): 82.0245120290513
Rule of 40 score: -5729.7344947235115
Altman Z-score: 18.752801716506916 (Safe Zone)
Piotroski F-score: 5 (Neutral)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.035016206463997536
Total shareholder yield (%): 0.035016206463997536 (Low Return)
Momentum (%): 1m 12.676056338028163, 3m 12.314480545527479, 6m 14.192495921696576, 12m 625.3886010362694, composite 190.09645329563773 (Strong Uptrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 7, recommendation: Neutral
Revenue growth 1y (%): -25.179751564199805
Revenue deceleration: no
Accrual ratio: -0.01071868931859629
FCF conversion rate: 0.9375947040933661
Beneish M-score: -2.1104243805578133 (Likely Safe)
ROE (%): -21.4329312532966
Net margin (%): -5344.801838024125
Asset turnover: 0.0032135763911961667
Equity multiplier (leverage): 1.2478469869333586
ROE archetype: Low Return
Treasury beta 1y: 0.001018749115204523 (R-squared: 1.337588566376024e-05)
Insider 90-day net shares: -5000 (net value USD: -140000.00)
ROIC (%): -1206.6817906428812 (pretax: -1527.445304611242)
Incremental ROIC 3y (%): -84.97828109277998 (pretax: -107.56744442124048)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 45.12635379061371, ROIC 42.7797833935018, revenue growth 1y 21.660649819494584, 6m momentum 18.501805054151625
Sector percentiles: P/E , 6m momentum 17.65759312320917
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.05
Base cash flow: -240482000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ALV.AX (Basic Materials — Other Precious Metals & Mining, Australia)
Report date: 2024-12-31 (annual)
Stock price: 0.01388888888888889
Market cap: 4878760 (USD: 3030285.714285714)
P/B ratio: 9.701150707880903
Debt to equity: 0
Current ratio: 6.4
Interest coverage ratio: -7577.041795665635
Return on net tangible assets (%): -309.15414638169796
Buffett classification: The Gruesome
Rule of 40 score: -20283.29740411389
Piotroski F-score: 0 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -32.87037037037037, 3m -35.18518518518518, 6m -66.20370370370371, 12m -30.09259259259259, composite -32.41698595146871 (Flat)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 2, recommendation: Neutral
Revenue deceleration: no
Accrual ratio: -0.1033159246111147
FCF conversion rate: 0.9492246620908008
Beneish M-score: -2.4788583534660193 (Likely Safe)
ROE (%): -244.78046864378885
Net margin (%): -21368.27899038893
Asset turnover: 0.00952236663903386
Equity multiplier (leverage): 1.2029908318338196
ROE archetype: Low Return
Treasury beta 1y: 0.07982244259312447 (R-squared: 0.01808743549976009)
Insider 90-day net shares: 816328 (net value USD: 27510.00)
ROIC (%): -1003.0992887011928 (pretax: -1269.745935064801)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 50.429799426934096, ROIC 50.71633237822349, revenue growth 1y , 6m momentum 74.78510028653295
Sector percentiles: P/E , 6m momentum 80.39977790116602
Industry median P/E: 8.740359897172237; industry median ROIC: -12.638421644657798
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.10575000000000001
Base cash flow: -2840249.0683229812
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ALXO (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 2.03
Market cap: 273162720 (USD: 273162720)
P/B ratio: 1.7870949749251719
Debt to equity: 0.0862
Current ratio: 7.21
Interest coverage ratio: -57.299093655589125
Return on net tangible assets (%): -11.778892214579741
Buffett classification: The Gruesome
Analyst consensus upside (%): 128.85572139303483
Rule of 40 score: 0
Altman Z-score: 0.7519708853001292 (Distress Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.4528436383998519
Total shareholder yield (%): 0.4528436383998519 (Low Return)
Momentum (%): 1m 13.407821229050265, 3m 21.5568862275449, 6m 44.99999999999999, 12m 275.92592592592587, composite 99.34612256967546 (Strong Uptrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 10, recommendation: Strong Short (Melting Ice Cube)
Revenue deceleration: no
Accrual ratio: 0.00649607791923294
FCF conversion rate: 1.043007753667652
Beneish M-score: -1.7831684052974373 (Likely Safe)
ROE (%): -20.219029143733646
Asset turnover: 0
Equity multiplier (leverage): 1.3386154470811151
ROE archetype: Low Return
Treasury beta 1y: -0.004027235275514636 (R-squared: 0.00022312616987649238)
Insider 90-day net shares: -1404 (net value USD: -2864.00)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E , P/B 21.028880866425993, ROIC , revenue growth 1y , 6m momentum 9.566787003610107
Sector percentiles: P/E , 6m momentum 7.378223495702006
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.07412088907292583
Base cash flow: -101201000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ANIK (Healthcare — Drug Manufacturers - Specialty & Generic, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 14.95
Market cap: 198919072 (USD: 198919072)
P/B ratio: 1.440852181835834
Debt to equity: 0.19219999999999998
Current ratio: 4.46
Return on net tangible assets (%): -4.084947611351008
Buffett classification: The Gruesome
Analyst consensus upside (%): 20.689655172413794
Rule of 40 score: -46.90037821401334
Altman Z-score: 3.60859716471456 (Safe Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 4.368610768503887
Debt paydown yield (%): 0.2573911062685834
Total shareholder yield (%): 4.62600187477247 (Moderate Return)
Momentum (%): 1m 1.4935505770536242, 3m -2.732595966167859, 6m 60.580021482277104, 12m 32.183908045977, composite 29.36205076885339 (Strong Uptrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 8, recommendation: Short
Revenue growth 1y (%): 13.161112809538377
Revenue deceleration: no
Accrual ratio: 0.006606124055543382
FCF conversion rate: 1.2414952531645569
Beneish M-score: -2.507313653874064 (Likely Safe)
ROE (%): -3.6457244218829996
Net margin (%): -17.074159124679184
Asset turnover: 0.16021338700470977
Equity multiplier (leverage): 1.3327408550435165
ROE archetype: Low Return
FCF z-score: 1.5230969877281952
Treasury beta 1y: 0.04315428164924475 (R-squared: 0.1128069358966259)
Insider 90-day net shares: 17200 (net value USD: 223201.00)
ROIC (%): -7.77878858079692 (pretax: -9.84656782379357)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 34.31085043988269, ROIC 69.79472140762464, revenue growth 1y 21.700879765395893, 6m momentum 5.865102639296188
Sector percentiles: P/E , 6m momentum 4.9426934097421205
Industry median P/E: 0.8814835040505258; industry median ROIC: 5.747543732928968
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.05840906434294676
Base cash flow: -11977000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for ANOR.V (Basic Materials — Other Industrial Metals & Mining, Canada)
Report date: 2025-12-31 (quarterly)
Stock price: 0.07092198581560284
Market cap: 18164254 (USD: 13258579.562043795)
P/B ratio: 3.846637241277077
Debt to equity: 0
Current ratio: 327.25
Interest coverage ratio: -422.32299270072997
Return on net tangible assets (%): -11.559762712133605
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: 1825.995976643324 (Safe Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -28.06484295845998, 3m 21.453900709219873, 6m 39.817629179331284, 12m 221.51300236406627, composite 136.07329556535433 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 4, short score 9, recommendation: Short
Revenue deceleration: no
Accrual ratio: 0.025295346106547465
FCF conversion rate: 1.2324752583819942
Beneish M-score: -2.0439856239838035 (Likely Safe)
ROE (%): -11.053630419528732
Asset turnover: 0
Equity multiplier (leverage): 1.0158768245412033
ROE archetype: Low Return
Treasury beta 1y: 0.024478077290351296 (R-squared: 0.0034679430070743656)
Insider 90-day net shares: 395000 (net value USD: 28210.00)
Incremental ROIC 3y (%): -11.267150381193822 (pretax: -14.26221567239723)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 39.966694421315566, ROIC , revenue growth 1y , 6m momentum 5.828476269775187
Sector percentiles: P/E , 6m momentum 5.58023320377568
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.15
Base cash flow: -715527.2727272727
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for AVAV (Industrials — Aerospace & Defense, United States)
Report date: 2026-04-30 (annual)
Stock price: 149.51
Market cap: 7566406656 (USD: 7566406656)
P/B ratio: 2.2428820131351697
Debt to equity: 0.18969999999999998
Current ratio: 4.3
Interest coverage ratio: -12.522180652057724
Return on net tangible assets (%): -6.411020210953879
Buffett classification: The Gruesome
Analyst consensus upside (%): 15.767613578094553
Rule of 40 score: 130.62780012238943
Altman Z-score: 4.06092636535154 (Safe Zone)
Piotroski F-score: 7 (Neutral)
Magic formula: return on capital % 3.3138043074043657, earnings yield % 0.7356043186940568, rank 1854
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -0.11598636445268003
Total shareholder yield (%): -0.11598636445268003 (Minimal or Negative)
Momentum (%): 1m 5.155436770291169, 3m -23.82820460566538, 6m -51.41835905767669, 12m -44.870943952802364, composite -40.94010332534214 (Strong Downtrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 8, short score 1, recommendation: Long
Revenue growth 1y (%): 140.89446240496594
Net income growth 1y (%): -707.8131089662761
Revenue CAGR 3y (%): 54.06926060983144
Revenue deceleration: no
Revenue growth consistency score: 59.523723591388695
Accrual ratio: -0.029397530519682524
FCF conversion rate: 0.620929232579718
Beneish M-score: -0.8365654036296413 (Strong Manipulation Signal)
ROE (%): -10.029380127170763
Net margin (%): -13.411370137770032
Asset turnover: 0.5782523504495701
Equity multiplier (leverage): 1.2932531251259007
ROE archetype: Low Return
Treasury beta 1y: -0.012726262560525265 (R-squared: 0.00567427936405256)
Insider 90-day net shares: -1048 (net value USD: -162544.00)
ROIC (%): -1.2063444026060137 (pretax: -1.5270182311468528)
Incremental ROIC 3y (%): -0.9357725924108128 (pretax: -1.1845222688744466)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 20.27027027027027, ROIC 54.054054054054056, revenue growth 1y 2.2522522522522523, 6m momentum 66.21621621621621
Sector percentiles: P/E , 6m momentum 83.56374807987712
Industry median P/E: 27.773289779307788; industry median ROIC: 6.974431518937386
Sector median P/E: 0.48479532163742683; sector median ROIC: 7.0952301251284755
WACC: 0.11211642880923758
Base cash flow: -62629000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for AVCN.TO (Healthcare — Drug Manufacturers - Specialty & Generic, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 0.09929078014184399
Market cap: 16981904 (USD: 12217197.12230216)
P/B ratio: 1.4752302450033414
Debt to equity: 0
Current ratio: 0.96
Interest coverage ratio: -19.78468531916256
Return on net tangible assets (%): -4.597527820684701
Buffett classification: The Gruesome
Rule of 40 score: -15.789526019830781
Altman Z-score: -5.37365543006543 (Distress Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 8.456082924168047, 3m -9.314420803782482, 6m -37.717601547388774, 12m -51.77304964539007, composite -34.1884071821141 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 10, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): 8.66607622269897
Net income growth 1y (%): -497.7576921880812
Revenue deceleration: no
Accrual ratio: 0.03118949468649959
FCF conversion rate: 3.355385174544385
Beneish M-score: -2.396930898396882 (Likely Safe)
ROE (%): -2.3735438110998124
Net margin (%): -4.324756026544791
Asset turnover: 0.3061856191051303
Equity multiplier (leverage): 1.7924656875624143
ROE archetype: Low Return
Treasury beta 1y: 0.0020129415790649113 (R-squared: 0.00016483863911267486)
Insider 90-day net shares: -1516479 (net value USD: -187138.00)
ROIC (%): -19.792262964655457 (pretax: -25.053497423614502)
Incremental ROIC 3y (%): 108.8631731497375 (pretax: 137.80148499966774)
Capital allocation category: Turnaround Compounder
Industry percentiles: P/E , P/B 35.19061583577713, ROIC 75.65982404692082, revenue growth 1y 28.152492668621704, 6m momentum 77.41935483870968
Sector percentiles: P/E , 6m momentum 63.96848137535817
Industry median P/E: 0.8814835040505258; industry median ROIC: 5.747543732928968
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.06505
Base cash flow: -1658382.4817518247
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for AVNS (Healthcare — Medical Devices, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 24.99
Market cap: 1170726912 (USD: 1170726912)
P/E ratio: 32.17342657647059
P/B ratio: 0.8391994657460683
Debt to equity: 0.177
Current ratio: 2.48
Interest coverage ratio: 5.933333333333334
Return on net tangible assets (%): 4.023408924652524
Buffett classification: The Good
Rule of 40 score: -10.422973557629584
Altman Z-score: 2.0110027835825157 (Grey Zone)
Piotroski F-score: 6 (Neutral)
Magic formula: return on capital % 2.584954981121115, earnings yield % 0.7160375628220785, rank 2045
Dividend yield (%): 0
Buyback yield (%): 0.11104212149519631
Debt paydown yield (%): -0.7943782537733275
Total shareholder yield (%): -0.6833361322781312 (Minimal or Negative)
Momentum (%): 1m 0.16032064128256174, 3m 1.3381995133819884, 6m 90.90909090909089, 12m 110.35353535353534, composite 67.42137514643595 (Strong Uptrend)
Lynch category: Asset Play (confidence: Medium)
Screener: long score 4, short score 5, recommendation: Neutral
Revenue growth 1y (%): 8.776119402985083
Net income growth 1y (%): -22.72727272727273
Revenue deceleration: no
Accrual ratio: 0.02043506921555702
FCF conversion rate: -3.2549019607843137
Beneish M-score: -2.39683793020269 (Likely Safe)
ROE (%): 0.6537204383772351
Net margin (%): 2.7991218441273324
Asset turnover: 0.17157924474997646
Equity multiplier (leverage): 1.361148497083894
ROE archetype: Low Return
FCF z-score: 4.507808591860037
Treasury beta 1y: -0.0006466685314233847 (R-squared: 1.3384238620872339e-05)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): 1.4881957186544341 (pretax: 1.8837920489296636)
Capital allocation category: Standard Allocator
Industry percentiles: P/E 23.738872403560833, P/B 11.572700296735905, ROIC 30.56379821958457, revenue growth 1y 30.56379821958457, 6m momentum 1.1869436201780417
Sector percentiles: P/E 28.43839541547278, 6m momentum 2.650429799426934
Industry median P/E: 21.626420273203117; industry median ROIC: -5.9391058628332924
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.11639933059700822
Base cash flow: -65600000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for B.V (Basic Materials — Other Industrial Metals & Mining, Canada)
Report date: 2026-02-28 (quarterly)
Stock price: 0.10638297872340426
Market cap: 36466820 (USD: 26618116.788321167)
P/B ratio: 1.5330974546221423
Debt to equity: 0
Current ratio: 15.66
Interest coverage ratio: -311.3277027027027
Return on net tangible assets (%): -0.9222786635922384
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: 49.466506685081384 (Safe Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -39.57446808510639, 3m -46.02048857368006, 6m -26.59574468085108, 12m 80.85106382978724, composite 42.22651379778541 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 4, short score 9, recommendation: Short
Revenue deceleration: no
Accrual ratio: 0.006152617696580071
FCF conversion rate: 2.76991625509985
Beneish M-score: -2.475450757416947 (Likely Safe)
ROE (%): -0.35364370473120355
Asset turnover: 0
Equity multiplier (leverage): 1.0173226622960923
ROE archetype: Low Return
Treasury beta 1y: -0.023673201018860984 (R-squared: 0.008145583059828997)
Insider 90-day net shares: 230000 (net value USD: 25760.00)
ROIC (%): -0.5859107494250714 (pretax: -0.7416591764874321)
Incremental ROIC 3y (%): 0.7222934939340068 (pretax: 0.9142955619417809)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 22.481265611990008, ROIC 8.076602830974188, revenue growth 1y , 6m momentum 40.049958368026644
Sector percentiles: P/E , 6m momentum 51.58245419211549
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.1492
Base cash flow: -1409360.5839416056
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for BBOT (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 8.82
Market cap: 706544640 (USD: 706544640)
P/B ratio: 1.9258584420328781
Debt to equity: 0.0070999999999999995
Current ratio: 6.16
Return on net tangible assets (%): -11.266788438809499
Buffett classification: The Gruesome
Analyst consensus upside (%): 182.68156424581008
Rule of 40 score: 0
Altman Z-score: 8.284741587835065 (Safe Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.017267132618825044
Total shareholder yield (%): 0.017267132618825044 (Low Return)
Momentum (%): 1m 18.548387096774192, 3m 0.4555808656036552, 6m -30.110935023771784, 12m -17.800559179869524, composite -20.105683445701896 (Strong Downtrend)
Lynch category: Turnaround (confidence: Medium)
Screener: long score 4, short score 9, recommendation: Short
Revenue deceleration: no
Accrual ratio: -0.01423743139648071
FCF conversion rate: 0.8535838122832851
Beneish M-score: 1.9555578551967792 (Strong Manipulation Signal)
ROE (%): -10.749882559588244
Asset turnover: 0
Equity multiplier (leverage): 1.1055061681746696
ROE archetype: Low Return
Treasury beta 1y: -0.0008134905781581545 (R-squared: 2.6764729952792787e-05)
Insider 90-day net shares: 0 (net value USD: 0.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 22.653429602888085, ROIC , revenue growth 1y , 6m momentum 51.624548736462096
Sector percentiles: P/E , 6m momentum 58.202005730659025
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.06830737303561679
Base cash flow: -134040000
DCF price per share: base 0, conservative 0, aggressive 0